Preliminary results of a phase II neoadjuvant trial with gemcitabine/oxaliplatin and cetuximab followed by surgery or concurrent intensity modulated radiation therapy (IMRT) with capecitabine for patients with borderline resectable and unresectable nonmetastatic pancreatic cancer

被引：0
|
作者：
Chaudhary, U. B. [1 ]
Gudena, V. [1 ]
Milling, D. L. [1 ]
O'Brien, P. [1 ]
Montero, A. J. [1 ]
Brashears, J. [1 ]
Marshall, D. [1 ]
Hoffman, B. [1 ]
Garrett-Mayer, E. [1 ]
Esnaola, N. [1 ]
机构：
[1] Med Univ S Carolina, Charleston, SC 29425 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2008年 / 26卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
15506
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Phase I-II trial of concurrent capecitabine and oxaliplatin with preoperative intensity-modulated radiotherapy in patients with locally advanced rectal cancer
    Javier Aristu, Jose
    Arbea, Leire
    Rodriguez, Javier
    Luis Hernandez-Lizoain, Jose
    Javier Sola, Jesus
    Moreno, Marta
    Diego Azcona, Juan
    Antonio Diaz-Gonzalez, Juan
    Miguel Garcia-Foncillas, Jesus
    Martinez-Monge, Rafael
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2008, 71 (03): : 748 - 755
  • [42] Cetuximab in combination with intensity modulated radiotherapy (IMRT) and gemcitabine for patients with locally advanced pancreatic cancer: A prospective phase II trial [PARC-Study ISRCTN56652283]
    Krempien, R.
    Munter, M. W.
    Timke, C.
    Friess, H.
    Hartung, G.
    Herfarth, K. K.
    Abdollahi, A.
    Buchler, M. W.
    Huber, P. E.
    Debus, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [43] Phase I radiation dose-escalation trial of intensity-modulated radiotherapy (IMRT) with concurrent fixed dose-rate gemcitabine (FDR-G) for unresectable pancreatic cancer
    Ben-Josef, E.
    Griffith, K.
    Francis, I. R.
    Khan, G.
    Lawrence, T. S.
    Abrams, R.
    Leslie, W.
    Zalupski, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [44] Compliance and safety of neoadjuvant intensity modulated radiotherapy (IMRT) with concurrent capecitabine for locally advanced rectal cancer: Updated results from a phase II trial (ChiCTR-TNC-10001094).
    Li, Yongheng
    Wang, Lin
    Li, Ziyu
    Li, Zhongwu
    Sun, Yingshi
    Gu, Jin
    Ji, Jiafu
    Cai, Yong
    Li, Xiaofan
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [45] Neoadjuvant S-1 With Concurrent Radiotherapy Followed by Surgery for Borderline Resectable Pancreatic Cancer A Phase II Open-label Multicenter Prospective Trial (JASPAC05)
    Takahashi, Shinichiro
    Ohno, Izumi
    Ikeda, Masafumi
    Konishi, Masaru
    Kobayashi, Tatsushi
    Akimoto, Tetsuo
    Kojima, Motohiro
    Morinaga, Soichiro
    Toyama, Hirochika
    Shimizu, Yasuhiro
    Miyamoto, Atsushi
    Tomikawa, Moriaki
    Takakura, Norihisa
    Takayama, Wataru
    Hirano, Satoshi
    Otsubo, Takehito
    Nagino, Masato
    Kimura, Wataru
    Sugimachi, Keishi
    Uesaka, Katsuhiko
    ANNALS OF SURGERY, 2022, 276 (05) : E510 - E517
  • [46] Impact of neoadjuvant intensity-modulated radiation therapy on borderline resectable pancreatic cancer with arterial abutment; a prospective, open-label, phase II study in a single institution
    Masui, Toshihiko
    Nagai, Kazuyuki
    Anazawa, Takayuki
    Sato, Asahi
    Uchida, Yuichiro
    Nakano, Kenzo
    Yogo, Akitada
    Kaneda, Akihiro
    Nakamura, Naoto
    Yoshimura, Michio
    Mizowaki, Takashi
    Uza, Norimitsu
    Fukuda, Akihisa
    Matsumoto, Shigemi
    Kanai, Masashi
    Isoda, Hiroyoshi
    Mizumoto, Masaki
    Seo, Satoru
    Hata, Koichiro
    Taura, Kojiro
    Kawaguchi, Yoshiya
    Takaori, Kyoichi
    Uemoto, Shinji
    Hatano, Etsuro
    BMC CANCER, 2022, 22 (01)
  • [47] Impact of neoadjuvant intensity-modulated radiation therapy on borderline resectable pancreatic cancer with arterial abutment; a prospective, open-label, phase II study in a single institution
    Toshihiko Masui
    Kazuyuki Nagai
    Takayuki Anazawa
    Asahi Sato
    Yuichiro Uchida
    Kenzo Nakano
    Akitada Yogo
    Akihiro Kaneda
    Naoto Nakamura
    Michio Yoshimura
    Takashi Mizowaki
    Norimitsu Uza
    Akihisa Fukuda
    Shigemi Matsumoto
    Masashi Kanai
    Hiroyoshi Isoda
    Masaki Mizumoto
    Satoru Seo
    Koichiro Hata
    Kojiro Taura
    Yoshiya Kawaguchi
    Kyoichi Takaori
    Shinji Uemoto
    Etsuro Hatano
    BMC Cancer, 22
  • [48] Final results of a phase II trial [PARC-Study ISRCTN56652283] for patients with primary inoperable locally advanced pancreatic cancer combining intensity modulated radiotherapy (IMRT) with cetuximab and gemcitabine
    Munter, M.
    Timke, C.
    Abdollahi, A.
    Friess, H.
    Jaeger, D.
    Heeger, S.
    Buchler, M.
    Debus, J.
    Huber, P.
    Krempien, R.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [49] A phase II trial of gemcitabine, S-1 and LV combination (GSL) neoadjuvant chemotherapy for patients with borderline resectable and locally advanced pancreatic cancer
    Kei Saito
    Hiroyuki Isayama
    Yoshihiro Sakamoto
    Yousuke Nakai
    Kazunaga Ishigaki
    Mariko Tanaka
    Takeyuki Watadani
    Junichi Arita
    Naminatsu Takahara
    Suguru Mizuno
    Hirofumi Kogure
    Hideaki Ijichi
    Keisuke Tateishi
    Minoru Tada
    Kiyoshi Hasegawa
    Masashi Fukayama
    Norihiro Kokudo
    Kazuhiko Koike
    Medical Oncology, 2018, 35
  • [50] A phase II trial of gemcitabine, S-1 and LV combination (GSL) neoadjuvant chemotherapy for patients with borderline resectable and locally advanced pancreatic cancer
    Saito, Kei
    Isayama, Hiroyuki
    Sakamoto, Yoshihiro
    Nakai, Yousuke
    Ishigaki, Kazunaga
    Tanaka, Mariko
    Watadani, Takeyuki
    Arita, Junichi
    Takahara, Naminatsu
    Mizuno, Suguru
    Kogure, Hirofumi
    Ijichi, Hideaki
    Tateishi, Keisuke
    Tada, Minoru
    Hasegawa, Kiyoshi
    Fukayama, Masashi
    Kokudo, Norihiro
    Koike, Kazuhiko
    MEDICAL ONCOLOGY, 2018, 35 (07)
12345